The recent development of a proposed Generic Drug User Fee Act (GDUFA) is designed to improve FDA's oversight authority and
resources to expedite the review process and better regulate the increasingly global drug-manufacturing industry.
For several years, the production of drugs has been shifting away from US manufacturing facilities. The impact of this manufacturing
shift is not inconsequential and has led to concerns about the safety of these drug products.
With more than 80% of APIs coming into the United States from foreign facilities, concerns about the safety of these drugs
has become paramount. Chief among these supply concerns is effective regulatory oversight. Such oversight includes adequate
review of drug applications and regular inspection of all manufacturing facilities to ensure that GMPs are in place and being
followed. Inadequate resources and programs within FDA to perform these activities is a threat to patient safety and to the
competitiveness of compliant manufacturers. This is where GDUFA can start to make a difference.
The Bulk Pharmaceuticals Task Force (BPTF), an affiliate of the Society of Chemical Manufacturers and Affiliates (SOCMA),
and the European Fine Chemicals Group (EFCG), a sector group of the European Chemical Industry Council (CEFIC), have publicly
expressed concerns over the risk to public health associated with drugs produced at substandard foreign facilities. For years,
these industry groups have supported registration and foreign-inspection fees as a means for increasing revenues to FDA to
support more foreign inspections. More recently, a 2008 US Government Accountability Office (GAO) report pointed out that
in 2007, FDA inspected less than 8% of foreign establishments and estimated that, at that rate, it would take 13 years to
inspect all such establishments. Further, GAO noted that FDA lacked complete and accurate information on foreign drug-manufacturing
establishments; such information crucial to understanding the drug supply chain.
In 2011, FDA engaged BPTF, EFCG, and the Generic Pharmaceutical Association (GPhA) to negotiate a comprehensive Generic Drug
User Fee program. The end result of the negotiations was GDUFA, which is waiting for action by the US Congress in the current
A primary reason for proposing GDUFA was to improve approval times for abbreviated new drug applications (ANDAs), eliminate
the backlog of thousands of amendments and approvals, and ensure drugs (specifically, finished-dose and active ingredient)
were being manufactured according to cGMPs. In 2011, the average ANDA approval time had slipped to more than 30 months with
a backlog of more than 2000 applications; the backlog is increasing daily. Adequate FDA resources to provide effective reviews,
as well as holdups due to inadequate or nonexistent inspections of production sites, contributed to these delays. BPTF, along
with EFCG and GPhA, worked with FDA through a series of meetings to define performance goals, procedures, and funding to ensure
a sustainable, effective program for generic drugs.
As stated in the FDA letter published on the FDA website on Jan. 5, 2012, titled "Proposed Human Generic Drug Performance
Goals and Procedures Fiscal Years 2013 through 2017," there are three primary aims of the GDUFA program: safety, access, and
Safety will be enhanced by ensuring that industry participants, foreign or domestic, who participate in the US generic-drug system
are held to consistent high-quality standards and are inspected biennially, using a risk-based approach, with foreign and
Access will be enhanced by expediting the availability of low-cost, high-quality generic drugs by bringing greater predictability
to the review times for abbreviated new drug applications, amendments and supplements, increasing predictability and timeliness
in the review process.
Transparency will be enhanced by increasing FDA's ability to protect Americans in the complex global supply environment by requiring the
identification of facilities involved in the manufacture of generic drugs and associated API as well as improving the FDA's
communication and feedback with industry to expedite product access.
The improvements to safety and transparency are exactly what BPTF and EFCG have been advocating. All parties to the GDUFA
negotiations indicated that they were willing to pay fees for inspections and filings to provide the necessary resources to
ensure the FDA could meet the performance goals defined in GDUFA.